Tian et al. examined 90 COAD cases and found significantly higher CD47 expression in patients with T3–T4, N1–N2, and Tumor–Node–Metastasis (TNM) stage III–IV tumors (all p < 0.05), supporting a positive correlation with disease advancement [88]. Here, CD47 is linked to neoplasm.